There is a drug that could treat thousands but it’s still illegal

Support us and go ad-free

MDMA, more commonly referred to as ecstasy, is often thought of as a dangerous Schedule 1 drug – a potentially addictive “club drug” of abuse with no known medical use. But scientists argue that instead of demonising MDMA, we should be studying it for its potential uses in issues related to social behaviour.

A chequered history

Ecstasy was first developed by a pharmaceutical company in 1912. It affects many of the same neurotransmitters – the chemical messengers of the brain – that are targeted by other “club drugs”. However, ecstasy is unique in that it causes its users to experience a feeling of closeness and empathy, and enhances positive social interactions unlike any other drug in the same class.

In the 1970’s, because of these positive effects, ecstasy earned a reputation as an “empathogen” and scientists set out to study its potential therapeutic uses.

Unfortunately for researchers at the time, its recreational use skyrocketed in the early 1980’s, leading to the US Drug Enforcement Agency and European authorities calling emergency meetings to discuss its control. In 1985, MDMA was placed into the Schedule 1 category, making it subject to the most stringent regulation.

In 2004, however, things changed after 20 years of advocacy by a non-governmental group: The US Food and Drug Administration approved the first use of MDMA in humans as an Investigational New Drug. Researchers have been able to learn more about the drug since its status was approved, and the results so far look promising.

Thirty-one years after it was restricted, is it now time to take MDMA off the ‘banned substances shelf’ and begin again to unleash its therapeutic potential?

Read on...

Support us and go ad-free

A team of scientists who published a commentary piece in Cell this week certainly think so. The researchers argue that instead of ecstasy being demonized, it could be a useful part of the toolkit for treating post-traumatic stress disorder (PTSD) and other neuropsychiatric disorders.

We’ve learned a lot about the nervous system from understanding how drugs work in the brain – both therapeutic and illicit drugs

says Robert Malenka, a psychiatrist and neuroscientist at Stanford University.

If we start understanding MDMA’s molecular targets better, and the biotech and pharmaceutical industries pay attention, it may lead to the development of drugs that maintain the potential therapeutic effects for disorders like autism or PTSD but have less abuse liability.

The researchers still don’t know exactly how MDMA works in humans, and they certainly don’t condone its recreational use. But a small clinical trial in 2013 and other clinical cases show potential for the drug to be used as an adjunct to therapy in cases of PTSD. Malenka argues:

Drugs like MDMA should be the object of rigorous scientific study, and should not necessarily be demonized

Improved tools in recent years such as optogenetics, viral tracing methodologies, sophisticated molecular genetic techniques, and the ability to create knockout mice have contributed to the push for more research into MDMA. Says Malenka:

I started thinking five or six years ago that maybe we can actually attack how MDMA works in the brain in a more meaningful way, because now we have the tools to do it right

Ecstasy has not been the only “illegal” drug in the spotlight lately for its potential to be used as a therapeutic. Magic mushrooms have also recently been in the press for their potential to treat depression and, in 2014, LSD (lysergic acid diethylamide) celebrated its first clinical trial in over 40 years for its potential to treat various psychological problems.

Could treatments for social and psychological disorders be about to get an upheaval? It’s too early to tell, but if this research is anything to go by, it may soon be time for ecstasy and other back alley purchases to come out of the shadows and take their place on a doctor’s prescription pad.

Featured image via Wikimedia Commons

Support us and go ad-free

We need your help to keep speaking the truth

Every story that you have come to us with; each injustice you have asked us to investigate; every campaign we have fought; each of your unheard voices we amplified; we do this for you. We are making a difference on your behalf.

Our fight is your fight. You’ve supported our collective struggle every time you gave us a like; and every time you shared our work across social media. Now we need you to support us with a monthly donation.

We have published nearly 2,000 articles and over 50 films in 2021. And we want to do this and more in 2022 but we don’t have enough money to go on at this pace. So, if you value our work and want us to continue then please join us and be part of The Canary family.

In return, you get:

* Advert free reading experience
* Quarterly group video call with the Editor-in-Chief
* Behind the scenes monthly e-newsletter
* 20% discount in our shop

Almost all of our spending goes to the people who make The Canary’s content. So your contribution directly supports our writers and enables us to continue to do what we do: speaking truth, powered by you. We have weathered many attempts to shut us down and silence our vital opposition to an increasingly fascist government and right-wing mainstream media.

With your help we can continue:

* Holding political and state power to account
* Advocating for the people the system marginalises
* Being a media outlet that upholds the highest standards
* Campaigning on the issues others won’t
* Putting your lives central to everything we do

We are a drop of truth in an ocean of deceit. But we can’t do this without your support. So please, can you help us continue the fight?

The Canary Support us

Comments are closed